Last edition
News about " Phase 3 HERIZON-GEA-01 trial "
BeOne Medicines reports positive Phase 3 results showing improved overall survival with Ziihera-based regimens in patients with HER2-positive gastroesophageal adenocarcinoma.
Phase 3 HERIZON-GEA-01 Trial | 01/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members